Additionally, the administration of the prebiotic 2′-fucosyllactose, the most prevalent human milk oligosaccharide (HMO) present in human breast milk, has been demonstrated to counteract gut permeability and insulin resistance, improve lipid utilization, and decrease de novo lipogenesis, thus reducing the obesity-associated steatosis [58]. The gene discussed is INS; the disease is Obesity.